Compare LOB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | URGN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2014 | 2016 |
| Metric | LOB | URGN |
|---|---|---|
| Price | $39.48 | $43.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.00 | $29.29 |
| AVG Volume (30 Days) | 168.1K | ★ 796.8K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $35.52 | $129.09 |
| Revenue Next Year | $16.03 | $70.96 |
| P/E Ratio | $29.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.36 | $15.86 |
| 52 Week High | $44.53 | $50.81 |
| Indicator | LOB | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 47.51 |
| Support Level | $35.70 | $42.00 |
| Resistance Level | $42.56 | $43.93 |
| Average True Range (ATR) | 0.95 | 1.98 |
| MACD | -0.14 | -0.60 |
| Stochastic Oscillator | 19.60 | 21.23 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.